Ovid Therapeutics Inc. (OVID) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Ovid Therapeutics Inc. (OVID) Healthcare & Pipeline Overview

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company specializing in the development of novel therapies for severe neurological disorders. With a focused pipeline targeting conditions like fragile X syndrome and Angelman syndrome, Ovid leverages strategic collaborations to advance its drug candidates through clinical trials, addressing significant unmet medical needs within the biotechnology sector.

What Is the Investment Thesis for OVID?

Ovid Therapeutics Inc. presents an investment thesis centered on its specialized pipeline targeting high-unmet-need neurological disorders and strategic collaborations. The company's focus on conditions like fragile X syndrome, tuberous sclerosis complex, and Angelman syndrome addresses significant patient populations lacking effective treatments, offering substantial market potential upon successful development and commercialization. With OV101 in Phase 2A clinical trials, Ovid demonstrates progress in its lead asset, while other candidates like OV329, OV350, OV882, and OV815 provide multiple shots on goal across various neurological indications. The company's collaborations with partners such as AstraZeneca AB and H. Lundbeck A/S validate its scientific approach and provide potential non-dilutive funding or development expertise. Despite a current market capitalization of $489M and a negative profit margin of -339.3%, typical for a clinical-stage biopharmaceutical company, Ovid maintains a strong gross margin of 99.5%, indicating efficient management of its direct costs. The low beta of 0.18 suggests relatively low volatility compared to the broader market, which may appeal to certain investor profiles. Future clinical trial milestones and potential licensing agreements represent key catalysts for value creation.

Based on FMP financials and quantitative analysis

OVID Key Highlights

Market capitalization stands at $489M, reflecting its valuation as a clinical-stage biopharmaceutical company focused on neurological disorders.

• Reported a profit margin of -339.3%, which is characteristic of biotechnology companies in the research and development phase prior to product commercialization.
• Achieved a gross margin of 99.5%, indicating strong control over the direct costs associated with its research activities and intellectual property.
• Exhibits a Beta of 0.18, suggesting lower volatility relative to the overall market, which may be attributed to its specific development-stage profile.
• Does not currently pay a dividend, consistent with its status as a growth-oriented biopharmaceutical company reinvesting capital into its pipeline.

Who Are OVID's Competitors?

OVID is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are OVID's Key Strengths?

Focused and diverse pipeline addressing multiple neurological disorders with high unmet medical needs.

• Strategic collaborations with established pharmaceutical companies and academic institutions, enhancing development capabilities.
• Strong gross margin of 99.5%, indicating efficient management of direct costs related to research and development.
• OV101 in Phase 2A clinical trials, representing a lead asset with tangible progress in development.

What Are OVID's Weaknesses?

Significant negative profit margin of -339.3%, typical for a clinical-stage biotech, indicating reliance on external funding.

• Small employee base of 23, which may limit the scope and speed of parallel development efforts.
• Early-stage nature of much of its pipeline, with significant clinical and regulatory hurdles remaining.
• No commercialized products, meaning no current revenue from drug sales to offset R&D expenses.

What Could Drive OVID Stock Higher?

OVID catalyst: Release of Phase 2A clinical trial results for OV101 in fragile X syndrome, expected to provide key insights into the drug's efficacy and safety profile.

• Advancement of OV329 into later-stage clinical trials for tuberous sclerosis complex and infantile spasms, signaling progress in its development pathway.
• Initiation of new clinical studies or significant data readouts for OV350, OV882, or OV815, demonstrating pipeline progression and potential value creation.
• Formation of new strategic collaborations or expansion of existing partnerships, potentially providing additional funding or development expertise.
• Achievement of key regulatory milestones, such as orphan drug designations or fast-track status, for any of its pipeline candidates.

What Are the Key Risks for OVID?

Negative return on equity (-22.5%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for any of its drug candidates, particularly OV101, which could significantly impact the company's valuation and future prospects.
• Inability to secure additional funding or maintain existing collaborations, which are crucial for sustaining its research and development activities given its negative profit margin.
• Intense competition within the neurological disorders therapeutic area, potentially leading to market saturation or the development of superior alternative treatments by competitors.
• Adverse regulatory decisions or delays in the approval process for its drug candidates, extending development timelines and increasing costs.
• Dependence on the success of a limited number of pipeline assets, making the company highly susceptible to the outcomes of individual clinical programs.

What Are the Growth Opportunities for OVID?

• **Advancement of OV101 for Fragile X Syndrome:** OV101 is currently in Phase 2A clinical trials for fragile X syndrome, a leading inherited cause of intellectual disability and autism spectrum disorder. With an estimated prevalence of 1 in 4,000 males and 1 in 8,000 females, this condition represents a significant unmet medical need. Successful progression through clinical development and potential regulatory approval for OV101 could unlock a substantial market opportunity, providing the first targeted therapy for core symptoms of this disorder. The timeline for such development is typically several years, with Phase 3 trials and subsequent regulatory submissions being critical milestones.
• **Development of OV329 for Tuberous Sclerosis Complex and Infantile Spasms:** OV329, a GABA aminotransferase inhibitor, targets seizures associated with tuberous sclerosis complex (TSC) and infantile spasms. TSC is a rare genetic disease causing benign tumors in the brain and other organs, affecting approximately 1 in 6,000 live births, while infantile spasms are a severe form of epilepsy in infants. The development of OV329 offers a potential new therapeutic option for these challenging conditions, which often have limited effective treatments. Advancing this candidate through clinical trials could address critical needs in pediatric neurology, representing a significant growth driver.
• **Expansion into Broader Epilepsies with OV350:** Ovid's OV350 is a small molecule in development for treating various epilepsies. Epilepsy affects millions globally, with a significant portion of patients not achieving adequate seizure control with existing medications. By targeting a broader range of epilepsies, OV350 has the potential to address a large market segment if it demonstrates superior efficacy or a more favorable safety profile. Successful clinical development and subsequent market entry could establish Ovid as a key player in the broader epilepsy treatment landscape, offering substantial revenue potential over the long term.
• **Gene Therapy for Angelman Syndrome with OV882:** OV882 is a short hairpin RNA gene therapy designed for Angelman syndrome, a severe neurodevelopmental disorder caused by a loss of function of the UBE3A gene. Affecting approximately 1 in 15,000 live births, Angelman syndrome currently has no specific cure, and treatments are largely symptomatic. The development of a gene therapy represents a cutting-edge approach with the potential for disease modification rather than just symptom management. Successful clinical trials and regulatory approval for OV882 could position Ovid at the forefront of gene therapy for rare neurological disorders, tapping into a high-value, specialized market.
• **Addressing Kinesin-Family Neurological Disorders with OV815:** OV815 is being developed for the treatment of kinesin-family of proteins associated neurological disorder. Kinesin proteins play crucial roles in neuronal transport, and mutations can lead to a range of severe neurological conditions, often with significant disability and limited treatment options. By targeting this specific family of proteins, Ovid aims to develop a precision medicine approach for a group of rare genetic disorders. Success in this area could provide a critical therapy for a highly underserved patient population, establishing Ovid's expertise in highly specialized neurological therapeutics and expanding its intellectual property portfolio.

What Opportunities Does OVID Have?

• Successful advancement of pipeline candidates through clinical trials, leading to potential regulatory approvals and market entry.
• Expansion of existing collaborations or formation of new partnerships to accelerate development and commercialization efforts.
• Potential for orphan drug designations or fast-track status for therapies targeting rare neurological conditions, expediting market access.
• Addressing large and growing markets for neurological disorders, which continue to have significant unmet medical needs.

What Threats Does OVID Face?

• High risk of clinical trial failures, which can lead to significant financial losses and delays.
• Intense competition from larger pharmaceutical companies and other biotechnology firms developing similar or alternative therapies.
• Stringent regulatory approval processes, which can be lengthy, costly, and unpredictable.
• Reliance on external funding for continued research and development, posing risks related to capital availability and dilution.

What Are OVID's Competitive Advantages?

• Specialized pipeline targeting high-unmet-need neurological disorders, creating potential for orphan drug designations and market exclusivity.
• Proprietary drug candidates and intellectual property surrounding novel mechanisms of action for neurological conditions.
• Strategic license and collaboration agreements with established pharmaceutical companies and research institutions, validating its scientific approach and sharing development risks.
• Expertise in navigating complex clinical development pathways for central nervous system (CNS) disorders, a historically challenging therapeutic area.

What Does OVID Do?

Ovid Therapeutics Inc., incorporated in 2014 and headquartered in New York, New York, is a biopharmaceutical company dedicated to the discovery and development of impactful medicines for patients and families affected by neurological disorders across the United States. The company's strategic focus is on addressing conditions with high unmet medical needs, leveraging a pipeline of drug candidates designed to modulate critical neurological pathways. At the core of its development efforts is OV101, a drug candidate currently undergoing Phase 2A clinical trials for the treatment of fragile X syndrome, a genetic condition causing intellectual disability and behavioral challenges. Beyond OV101, Ovid's robust pipeline includes OV329, a GABA aminotransferase inhibitor being developed for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms, both severe neurological conditions. Additionally, OV350 is a small molecule in development for various epilepsies, aiming to provide new therapeutic options for patients experiencing chronic seizures. Expanding its therapeutic modalities, Ovid is also advancing OV882, a short hairpin RNA gene therapy designed to treat Angelman syndrome, a complex genetic disorder affecting the nervous system. Furthermore, OV815 is under development for kinesin-family of proteins associated neurological disorder, highlighting the company's commitment to rare and challenging neurological conditions. To bolster its research and development capabilities, Ovid Therapeutics has established a network of license and collaboration agreements with notable partners including Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. These collaborations are instrumental in accelerating the development and potential commercialization of its innovative therapies, positioning Ovid as a key player in the specialized neurological therapeutics market.

What Products and Services Does OVID Offer?

• Develops drug candidates for neurological disorders in the United States.
• Focuses on conditions like fragile X syndrome, tuberous sclerosis complex, infantile spasms, epilepsies, and Angelman syndrome.
• Advances OV101, a drug candidate in Phase 2A clinical trials for fragile X syndrome.
• Is developing OV329, a GABA aminotransferase inhibitor, for seizures associated with tuberous sclerosis complex and infantile spasms.
• Works on OV350, a small molecule therapy for various epilepsies.
• Explores gene therapy with OV882 for Angelman syndrome.
• Develops OV815 for kinesin-family of proteins associated neurological disorder.
• Engages in license and collaboration agreements with other pharmaceutical companies and academic institutions.

How Does OVID Make Money?

• Primarily generates value through the research, development, and clinical advancement of novel drug candidates for neurological disorders.
• Relies on securing license and collaboration agreements with pharmaceutical partners, potentially involving upfront payments, milestone payments, and future royalties.
• Aims to eventually commercialize approved therapies, generating revenue from product sales in the United States.
• Invests heavily in preclinical and clinical trials to demonstrate the safety and efficacy of its pipeline assets.
• Leverages intellectual property protection for its drug candidates to maintain market exclusivity upon approval.

What Industry Does OVID Operate In?

Ovid Therapeutics Inc. operates within the dynamic and research-intensive Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by significant investment in R&D, long development cycles, and high regulatory hurdles, particularly for novel drug candidates. Ovid's specific niche in neurological disorders places it within a market segment with substantial unmet medical needs and a growing patient population. The competitive landscape is intense, featuring both large pharmaceutical companies with established neurological franchises and numerous smaller biotechs vying for breakthroughs. Market trends indicate a strong focus on rare diseases, gene therapies, and precision medicine approaches, areas where Ovid's pipeline, including OV882 for Angelman syndrome, aligns. The company's strategy of developing targeted therapies for specific neurological conditions positions it to potentially capture value in specialized markets, differentiating itself from broader-spectrum drug developers. Success in this industry is heavily reliant on clinical trial outcomes and regulatory approvals.

Who Are OVID's Key Customers?

• Patients suffering from rare and common neurological disorders, including fragile X syndrome, tuberous sclerosis complex, infantile spasms, and various epilepsies.
• Families and caregivers seeking effective treatments for severe neurodevelopmental and neurological conditions.
• Healthcare providers, including neurologists, pediatric neurologists, and epileptologists, who prescribe therapies for these disorders.
• Potential pharmaceutical partners interested in licensing or co-developing Ovid's drug candidates for broader market access.

Company Profile

Ovid Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Margaret Alexander. OVID has traded publicly since 2017.

Ovid Therapeutics Inc. Financial Trajectory

Ovid Therapeutics Inc. (OVID) reported $733K in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $15.0M, with diluted EPS of $-0.20. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, OVID averaged $-0.12 in diluted EPS.

How Ovid Therapeutics Inc. Is Valued

Ovid Therapeutics Inc. carries a market capitalization of $489M, placing it in the small-cap category. Analyst price targets span from $4.00 to $8.00, with a consensus of $6.00. At the current price of $2.62, that implies approximately 129% upside potential. Relative to its peer group, OVID's quantitative score of 30/100 is below the peer average of 80/100.

Return on equity for Ovid Therapeutics Inc. stands at -22.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.5%, the inverse of the P/E and a quick read on earnings relative to price.

Ovid Therapeutics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.64 places it in the safe zone, indicating low near-term bankruptcy risk.

Ovid Therapeutics Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 31.6% above estimates on average.

Over the past six months, Ovid Therapeutics Inc. insiders filed 7 SEC Form 4 transactions — 1 sales and 6 purchases. On net that is roughly 224K shares acquired (about $406K) — insiders putting money in tends to read as conviction.

OVID Financials

OVID Latest News

OVID Analyst Consensus

OVID MoonshotScore

OVID Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources